InsightsPremium

Robert Kotin

Advisor & co-Founder at Generation Bio

Rob has been a leader in adeno-associated virus (AAV) research for over 30 years, beginning as a post-doctoral fellow at Cornell University Medical Center (now Weill), where he discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) as a tenure track inves tigator then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy. While at the NIH, Rob's laboratory invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which was licensed by several companies and was used to produce Glybera™, the first rAAV product granted regulatory agency approval for sale. The research at the NIH resulted in the discovery of an AAV replicative product that has been described as closed-ended linear duplex DNA. Rob served as vice president of virology and gene therapy at Voyager Therapeutics from 2014 to 2016. Rob earned his Bachelor of Arts in biology from the University of California, Santa Cruz and his doctorate from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School) in microbiology.

Roles

  • Advisor & co-Founder

    Current role

Social

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.